

NOVARTIS - String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)

<https://marketpublishers.com/r/N23E897AAF4EN.html>

Date: August 2013

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: N23E897AAF4EN

Abstracts

Novartis received break through designation from FDA for its third pipeline molecule BYM338 based on PhII proof of concept study data targeting rare, serious debilitating disease - sporadic inclusion body myositis (sIBM). Earlier it has received the break through designation for serelaxin in acute heart failure and LDK378 for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic NSCLC. Company planned to start Ph2/3 – 52 wk study targeted to enroll 240 patients by next month and the drug is expected to launch in 2016. Considering no medical option exists and rarity of disease, we expect bimagrumab to generate the global peak sales of \$500m.

I would like to order

Product name: NOVARTIS - String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)

Product link: <https://marketpublishers.com/r/N23E897AAF4EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N23E897AAF4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

